Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Harbour Biomed Us, Inc.

Clinical trials sponsored by Harbour Biomed Us, Inc., explained in plain language.

Now part of HBM Holdings Limited 2142 HKEX

Biopharma developing antibody-based therapies for cancer and autoimmune diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

New cancer drug HBM1020 tested in tiny early trial

Disease control Completed

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:28 UTC